Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3977911 | Brachytherapy | 2010 | 8 Pages |
Abstract
Low pretreatment testosterone level may be a marker for men at increased risk of premature death with ADT. The combination of low pretreatment serum testosterone level and multiple preexisting comorbidities is associated with decreased OS when ADT is incorporated into treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Al V. Taira, Gregory S. Merrick, Robert W. Galbreath, Wayne M. Butler, Kent E. Wallner,